{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:58:52Z","timestamp":1790654332713,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10549-026-08084-3","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:11:10Z","timestamp":1790604670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Geographic access to triple negative breast cancer clinical trials: are trials located near patients?"],"prefix":"10.1007","volume":"219","author":[{"given":"Laura Burns","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Kelsey","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Levit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin P.","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Michael","family":"Waterhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Garrett-Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7189-0763","authenticated-orcid":false,"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"1","key":"8084_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clinicians"},{"issue":"3","key":"8084_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2023.25881","volume":"331","author":"JL Caswell-Jin","year":"2024","unstructured":"Caswell-Jin JL, Sun LP, Munoz D, Lu Y, Li Y, Huang H, Hampton JM, Song J, Jayasekera J, Schechter C, Alagoz O, Stout NK, Trentham-Dietz A, Lee SJ, Huang X, Mandelblatt JS, Berry DA, Kurian AW, Plevritis SK (2024) Analysis of breast cancer mortality in the US\u20141975 to 2019. JAMA 331(3):233\u2013241. https:\/\/doi.org\/10.1001\/jama.2023.25881","journal-title":"JAMA"},{"key":"8084_CR3","unstructured":"SEER*Explorer: an interactive website for SEER cancer statistics. National Cancer Institute. 2025. https:\/\/seer.cancer.gov\/explorer\/"},{"issue":"9","key":"8084_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O\u2019shaughnessy J (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"issue":"3","key":"8084_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387(3):217\u2013226. https:\/\/doi.org\/10.1056\/NEJMoa2202809","journal-title":"N Engl J Med"},{"key":"8084_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/107497","volume":"2011","author":"GK Singh","year":"2011","unstructured":"Singh GK, Williams SD, Siahpush M, Mulhollen A (2011) Socioeconomic, rural-Urban, and racial inequalities in US cancer mortality: part I\u2014all cancers and lung cancer and part II\u2014colorectal, prostate, breast, and cervical cancers. J Cancer Epidemiol 2011:1\u201327. https:\/\/doi.org\/10.1155\/2011\/107497","journal-title":"J Cancer Epidemiol"},{"key":"8084_CR7","doi-asserted-by":"publisher","unstructured":"Balogh EP, Levit LA, Unger JM et al (2025) ASCO state of cancer care in America special report 2025: Access to cancer clinical trials in the United States. JCO Oncol Pract OP-25\u201300233. https:\/\/doi.org\/10.1200\/op-25-00233","DOI":"10.1200\/op-25-00233"},{"key":"8084_CR8","doi-asserted-by":"publisher","unstructured":"Duma N, Vera Aguilera J, Paludo J, Haddox CL, Gonzalez Velez M, Wang Y, Leventakos K, Hubbard JM, Mansfield AS, Go RS, Adjei AA (2018 Jan) Representation of minorities and women in oncology clinical trials: review of the past 14 years. J Oncol Pract 14(1):e1\u2013e10. https:\/\/doi.org\/10.1200\/jop.2017.025288","DOI":"10.1200\/jop.2017.025288"},{"issue":"2","key":"8084_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jgo.2019.07.017","volume":"11","author":"MS Sedrak","year":"2020","unstructured":"Sedrak MS, Mohile SG, Sun V, Sun C-L, Chen BT, Li D, Wong AR, George K, Padam S, Liu J, Katheria V, Dale W (2020) Barriers to clinical trial enrollment of older adults with cancer: a qualitative study of the perceptions of community and academic oncologists. J Geriatr Oncol 11(2):327\u2013334. https:\/\/doi.org\/10.1016\/j.jgo.2019.07.017","journal-title":"J Geriatr Oncol"},{"issue":"27","key":"8084_CR10","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/NEJM199912303412706","volume":"341","author":"LF Hutchins","year":"1999","unstructured":"Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061\u20132067. https:\/\/doi.org\/10.1056\/NEJM199912303412706","journal-title":"N Engl J Med"},{"key":"8084_CR11","doi-asserted-by":"publisher","unstructured":"Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K (2019 Oct 1) Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol 5(10):e191870. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1870","DOI":"10.1001\/jamaoncol.2019.1870"},{"issue":"22","key":"8084_CR12","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","volume":"291","author":"VH Murthy","year":"2004","unstructured":"Murthy VH, Krumholz HM, Gross CP (2004 Jun 9) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291(22):2720\u20132726. https:\/\/doi.org\/10.1001\/jama.291.22.2720","journal-title":"JAMA"},{"issue":"33","key":"8084_CR13","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","volume":"35","author":"ES Kim","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, Uldrick TS, Lichtman SM, Roach N, Beaver JA, Sridhara R, Hesketh PJ, Denicoff AM, Garrett-Mayer E, Rubin E, Multani P, Prowell TM, Schenkel C, Kozak M, Allen J, Sigal E, Schilsky RL (2017) Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and friends of Cancer research joint research statement. J Clin Oncol 35(33):3737\u20133744. https:\/\/doi.org\/10.1200\/JCO.2017.73.7916","journal-title":"JCO"},{"issue":"2","key":"8084_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.23157","volume":"112","author":"JG Ford","year":"2008","unstructured":"Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, Tilburt J, Baffi C, Tanpitukpongse TP, Wilson RF, Powe NR, Bass EB (2008) Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer: Interdiscip Int J Am Cancer Soc 112(2):228\u2013242. https:\/\/doi.org\/10.1002\/cncr.23157","journal-title":"Cancer: Interdiscip Int J Am Cancer Soc"},{"issue":"8","key":"8084_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.6004\/jnccn.2007.0067","volume":"5","author":"NJ Meropol","year":"2007","unstructured":"Meropol NJ, Buzaglo JS, Millard J, Damjanov N, Miller SM, Ridgway C, Ross EA, Sprandio JD, Watts P (2007 Sep) Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw 5(8):753\u2013762. https:\/\/doi.org\/10.6004\/jnccn.2007.0067","journal-title":"J Natl Compr Canc Netw"},{"issue":"19","key":"8084_CR16","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1200\/jco.22.00754","volume":"40","author":"RA Oyer","year":"2022","unstructured":"Oyer RA, Hurley P, Boehmer L, Bruinooge SS, Levit K, Barrett N, Benson A, Bernick LA, Byatt L, Charlot M, Crews J, DeLeon K, Fashoyin-Aje L, Garrett-Mayer E, Gralow JR, Green S, Guerra CE, Hamroun L, Hardy CM, Hempstead B, Jeames S, Mann M, Matin K, McCaskill-Stevens W, Merrill J, Nowakowski GS, Patel MI, Pressman A, Ramirez AG, Segura J, Segarra-Vasquez B, Hanley Williams J, Williams JE, Winkfield KM, Yang ES, Zwicker V, Pierce LJ (2022 Jul 1) Increasing racial and ethnic diversity in cancer clinical trials: an American society of clinical oncology and association of community cancer centers joint research statement. J Clin Oncol 40(19):2163\u20132171. https:\/\/doi.org\/10.1200\/jco.22.00754","journal-title":"JCO"},{"issue":"2","key":"8084_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamainternmed.2014.6300","volume":"175","author":"MD Galsky","year":"2015","unstructured":"Galsky MD, Stensland KD, McBride RB, Latif A, Moshier E, Oh WK, Wisnivesky J (2015 Feb) Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med 175(2):293\u2013295. https:\/\/doi.org\/10.1001\/jamainternmed.2014.6300","journal-title":"JAMA Intern Med"},{"key":"8084_CR18","unstructured":"Kirkwood MK, Schenkel C, Hinshaw DC et al (2024) State of geographic access to cancer treatment trials in the United States: are studies located where patients live? JCO Oncol Pract 20:OP.24.00261"},{"issue":"5","key":"8084_CR19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2023.7314","volume":"10","author":"H Lee","year":"2024","unstructured":"Lee H, Bates AS, Callier S, Chan M, Chambwe N, Marshall A, Terry MB, Winkfield K, Janowitz T (2024) Analysis and optimization of equitable US Cancer clinical trial Center access by travel Time. JAMA Oncol 10(5):652\u2013657. https:\/\/doi.org\/10.1001\/jamaoncol.2023.7314","journal-title":"JAMA Oncol"},{"key":"8084_CR20","unstructured":"ClinicalTrials.gov (2024) U.S. National Library of Medicine"},{"key":"8084_CR21","unstructured":"Bureau USC American community survey 5-year data (2009-2022)"},{"key":"8084_CR22","unstructured":"Agriculture USDo. Data from: rural-urban continuum codes. 2024"},{"key":"8084_CR23","unstructured":"Centers for disease control and Prevention\/Agency for toxic substances and disease Registry\/Geospatial research A, and services program (2022). CDC\/ATSDR Soc Vulnerability Index"},{"key":"8084_CR24","unstructured":"Lyons MP, Stevenson JR, Thurman L, Young B (2024) Guidelines for using the climate change vulnerability index 2024 release 4.0. 2024"},{"issue":"7","key":"8084_CR25","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jamaoncol.2021.1254","volume":"7","author":"B Cho","year":"2021","unstructured":"Cho B, Han Y, Lian M, Colditz GA, Weber JD, Ma C, Liu Y (2021) Evaluation of racial\/ethnic differences in treatment and mortality among women with triple-negative breast cancer. JAMA Oncol 7(7):1016\u20131023. https:\/\/doi.org\/10.1001\/jamaoncol.2021.1254","journal-title":"JAMA Oncol"},{"key":"8084_CR26","doi-asserted-by":"publisher","first-page":"1058722","DOI":"10.3389\/fpubh.2022.1058722","volume":"10","author":"W Zhang","year":"2022","unstructured":"Zhang W, Bai Y, Sun C, Lv Z, Wang S (2022) Racial and regional disparities of triple negative breast cancer incidence rates in the United States: an analysis of 2011\u20132019 NPCR and SEER incidence data. Front Public Health 10:1058722. https:\/\/doi.org\/10.3389\/fpubh.2022.1058722","journal-title":"Front Public Health"},{"key":"8084_CR27","unstructured":"UC B (2022) County population totals: 2020-2021"},{"issue":"Pt 2","key":"8084_CR28","doi-asserted-by":"publisher","first-page":"106741","DOI":"10.1016\/j.ypmed.2021.106741","volume":"152","author":"BL Sprague","year":"2021","unstructured":"Sprague BL, Ahern TP, Herschorn SD, Sowden M, Weaver DL, Wood ME (2021 Nov) Identifying key barriers to effective breast cancer control in rural settings. Prev Med 152(Pt 2):106741. https:\/\/doi.org\/10.1016\/j.ypmed.2021.106741","journal-title":"Prev Med"},{"key":"8084_CR29","doi-asserted-by":"publisher","unstructured":"Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL (2018 Aug 3) Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials. JAMA Netw Open 1(4):e181235. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.1235","DOI":"10.1001\/jamanetworkopen.2018.1235"},{"issue":"11","key":"8084_CR30","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.22.01826","volume":"41","author":"JM Unger","year":"2023","unstructured":"Unger JM, LeBlanc M, George S, Wolmark N, Curran WJ, O\u2019Dwyer PJ, Schnall MD, Mannel RS, Mandrekar SJ, Dignam JJ, Gray RJ, Zhao F, Bah M, Vaidya R, Blanke CD (2023) Population, clinical, and scientific impact of national cancer Institute\u2019s national clinical trials network treatment studies. JCO 41(11):2020\u20132028. https:\/\/doi.org\/10.1200\/JCO.22.01826","journal-title":"JCO"},{"issue":"5","key":"8084_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10552-023-01683-1","volume":"34","author":"T Tran","year":"2023","unstructured":"Tran T, Rousseau MA, Farris DP, Bauer C, Nelson KC, Doan HQ (2023 May) The social vulnerability index as a risk stratification tool for health disparity research in cancer patients: a scoping review. Cancer Causes Control 34(5):407\u2013420. https:\/\/doi.org\/10.1007\/s10552-023-01683-1","journal-title":"Cancer Causes Control"},{"issue":"16_suppl","key":"8084_CR32","doi-asserted-by":"publisher","first-page":"6534","DOI":"10.1200\/JCO.2022.40.16_suppl.6534","volume":"40","author":"A Mehta","year":"2022","unstructured":"Mehta A, Jeon WJJ, Hino C, Lau E, Mirshahidi HR, Nagaraj G (2022) Association of U.S. county social vulnerability with cancer mortality. J Clin Oncol 40(16_suppl):6534\u20136534. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.6534","journal-title":"J Clin Oncol"},{"key":"8084_CR33","doi-asserted-by":"publisher","unstructured":"Grant SJ, Jansen M, Kuo T-M, Rubinstein SM, Wildes TM, Tuchman SA, Muss HB, Lichtman EI, Charlot M (2023) Cross-sectional analysis of clinical trial availability and North Carolina neighborhood social vulnerability. JCO Oncol Pract 19(2):e248\u2013e262. https:\/\/doi.org\/10.1200\/OP.22.00325","DOI":"10.1200\/OP.22.00325"},{"issue":"1","key":"8084_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijmedinf.2014.09.001","volume":"84","author":"LB Afrin","year":"2015","unstructured":"Afrin LB, Oates JC, Kamen DL (2015) Improving clinical trial accrual by streamlining the referral process. Int J Med Inf 84(1):15\u201323. https:\/\/doi.org\/10.1016\/j.ijmedinf.2014.09.001. 01\/1\/2015","journal-title":"Int J Med Inf"},{"issue":"5","key":"8084_CR35","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10552-013-0173-5","volume":"24","author":"CP Kaplan","year":"2013","unstructured":"Kaplan CP, N\u00e1poles AM, Dohan D, Shelley Hwang E, Melisko M, Nickleach D, Quinn JA, Haas J (2013) Clinical trial discussion, referral, and recruitment: physician, patient, and system factors. Cancer Causes Control 24(5):979\u2013988. https:\/\/doi.org\/10.1007\/s10552-013-0173-5","journal-title":"Cancer Causes Control"},{"issue":"6","key":"8084_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.7326\/m15-2658","volume":"165","author":"LM Schwartz","year":"2016","unstructured":"Schwartz LM, Woloshin S, Zheng E, Tse T, Zarin DA (2016 Sep 20) ClinicalTrials.Gov and drugs@FDA: a comparison of results reporting for new drug approval trials. Ann Intern Med 165(6):421\u2013430. https:\/\/doi.org\/10.7326\/m15-2658","journal-title":"Ann Intern Med"},{"issue":"3","key":"8084_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2168479018782885","volume":"53","author":"S Stergiopoulos","year":"2019","unstructured":"Stergiopoulos S, Getz KA, Blazynski C (2019) Evaluating the completeness of ClinicalTrials.Gov. Ther Innov Regul Sci 53(3):307\u2013317. https:\/\/doi.org\/10.1177\/2168479018782885","journal-title":"Ther Innov Regul Sci"},{"key":"8084_CR38","doi-asserted-by":"publisher","unstructured":"Nipp RD, Hong K, Paskett ED (2019) Overcoming barriers to clinical trial enrollment. 2019. Am Soc Clin Oncol Educ Book (39):105\u2013114. https:\/\/doi.org\/10.1200\/EDBK_243729","DOI":"10.1200\/EDBK_243729"},{"key":"8084_CR39","first-page":"6","volume":"38","author":"JS Brathwaite","year":"2024","unstructured":"Brathwaite JS, Goldstein D, Dowgiallo E, Haroun L, Hogue KA, Arakaki T (2024) Barriers to clinical trial enrollment: focus on underrepresented populations. Clin Res 38:6\u201315","journal-title":"Clin Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08084-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08084-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08084-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:54:29Z","timestamp":1790654069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08084-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8084"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08084-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study used publicly available, de-identified data from ClinicalTrials.gov and publicly available county-level datasets. No human participants were directly involved, and no individually identifiable information was collected or analyzed. Therefore, this study did not constitute human subjects research and did not require Institutional Review Board review or approval.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was presented in part in a poster presentation at the 2025 ASCO Annual Meeting.","order":3,"name":"Ethics","label":"Prior presentations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MCM has served as consultant for Astra Zeneca, Roche, Novartis, Pfizer and Exact Sciences. The rest of the authors report no competing interests to declare.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22"}}